NCT07095998 · Ka-Wai Ho
Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
What this study is about
This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS).
View original scientific description
This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.
- Participants must have adequate hematologic parameters to allow chemotherapy.
Exclusion criteria
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familial neuropathy;
- Any contraindication for treatment with cisplatin as determined by their primary oncologist;
- Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
- Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
- Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
- Patients not considered to be able to comply with the protocol. Inclusion Criteria Cohort B:
- Adults age ≥ 18 with a diagnosis of cis-PN.
- The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy. Exclusion Criteria Cohort B:
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familiar neuropathy;
- History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
- Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
- Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
- Patients not considered to be able to comply with the protocol.
Where
- Boston, Massachusetts
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 22, 2026 · Source of record for eligibility and locations